Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cancer diagnostics and therapeutics - Cellectar Biosciences

Next Previous
Drug Profile

Research programme: cancer diagnostics and therapeutics - Cellectar Biosciences

Alternative Names: 127I-CLR 1404; CLR 125; CLR 127; CLR 1401-boron-dipyrromethene analog; CLR 1404; CLR 1500 compounds - Cellectar Biosciences; CLR 1502; CLR 1601 PTX; CLR 1602; CLR 1602-PTX; CLR 1603; CLR 1603-PTX; CLR 1605-GEM; CLR 1700 series; CLR CTX; CLR1401; CLR1501; CLR1505; COLD; GLOW1; GLOW2; PDCs - Cellectar Biosciences; Phospholipid drug conjugates - Cellectar Biosciences; Phospholipid ether analogues - Cellectar Biosciences; PLEs - Cellectar Biosciences

Latest Information Update: 28 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Michigan Medical School
  • Developer Cellectar Biosciences
  • Class Antineoplastics; Drug conjugates; Imaging agents; Phospholipid ethers; Phospholipids; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Apoptosis modulators; CD244 antigen modulators; CD8 positive T lymphocyte modulators; Cell division modulators; DNA synthesis inhibitors; Gene modulators; Histone deacetylase inhibitors; Ionising radiation emitters; Positron-emission tomography enhancers; Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Breast cancer; Cancer; Solid tumours

Most Recent Events

  • 28 Jan 2024 No recent reports of development identified for preclinical development in Breast-cancer in USA (IV)
  • 28 Aug 2021 No recent reports of development identified for preclinical development in Cancer in USA (IV)
  • 28 Aug 2021 No recent reports of development identified for research development in Cancer(Metastatic disease) in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top